
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors.
The company revealed that the positive results from Part A will be used to determine the dose of AL102 to be evaluated in Part B of RINGSIDE Study.